Salvage Therapy With Temozolomide in an Immunocompetent Patient With Primary Brain Lymphoma

Temozolomide, an oral alkylating agent, is a suitable candidate for clinical study because it permeates the blood-brain barrier, has in vitro additive cytotoxic activity with radio-therapy, and shows only mild toxicity, even in patients older than 60 years of age.

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 2000-04, Vol.92 (7), p.575-576
Main Authors: Reni, Michele, Ferreri, Andrés José María, Landoni, Claudio, Villa, Eugenio
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents, Alkylating - therapeutic use
Brain
Brain Neoplasms - drug therapy
Brain Neoplasms - pathology
Cancer
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
Drug therapy
Humans
Immunocompetence
Lymphoma, B-Cell - drug therapy
Lymphoma, B-Cell - pathology
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Non-Hodgkin - drug therapy
Magnetic Resonance Imaging
Male
Medical research
Older people
Salvage Therapy
Temozolomide
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Temozolomide, an oral alkylating agent, is a suitable candidate for clinical study because it permeates the blood-brain barrier, has in vitro additive cytotoxic activity with radio-therapy, and shows only mild toxicity, even in patients older than 60 years of age.
ISSN:0027-8874
1460-2105
1460-2105
DOI:10.1093/jnci/92.7.575